Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
Genome Med. 2022 Jun 13;14(1):62. doi: 10.1186/s13073-022-01064-4.
Genomics enables individualized diagnosis and treatment, but large challenges remain to functionally interpret rare variants. To date, only one causative variant has been described for KCNK9 imprinting syndrome (KIS). The genotypic and phenotypic spectrum of KIS has yet to be described and the precise mechanism of disease fully understood.
This study discovers mechanisms underlying KCNK9 imprinting syndrome (KIS) by describing 15 novel KCNK9 alterations from 47 KIS-affected individuals. We use clinical genetics and computer-assisted facial phenotyping to describe the phenotypic spectrum of KIS. We then interrogate the functional effects of the variants in the encoded TASK3 channel using sequence-based analysis, 3D molecular mechanic and dynamic protein modeling, and in vitro electrophysiological and functional methodologies.
We describe the broader genetic and phenotypic variability for KIS in a cohort of individuals identifying an additional mutational hotspot at p.Arg131 and demonstrating the common features of this neurodevelopmental disorder to include motor and speech delay, intellectual disability, early feeding difficulties, muscular hypotonia, behavioral abnormalities, and dysmorphic features. The computational protein modeling and in vitro electrophysiological studies discover variability of the impact of KCNK9 variants on TASK3 channel function identifying variants causing gain and others causing loss of conductance. The most consistent functional impact of KCNK9 genetic variants, however, was altered channel regulation.
This study extends our understanding of KIS mechanisms demonstrating its complex etiology including gain and loss of channel function and consistent loss of channel regulation. These data are rapidly applicable to diagnostic strategies, as KIS is not identifiable from clinical features alone and thus should be molecularly diagnosed. Furthermore, our data suggests unique therapeutic strategies may be needed to address the specific functional consequences of KCNK9 variation on channel function and regulation.
基因组学能够实现个体化诊断和治疗,但在功能上解释罕见变异仍存在巨大挑战。迄今为止,仅描述了 KCNK9 印迹综合征(KIS)的一个致病变异。KIS 的基因型和表型谱尚未描述,疾病的精确机制也尚未完全理解。
本研究通过描述 47 名 KIS 患者中的 15 个新的 KCNK9 改变,发现 KCNK9 印迹综合征(KIS)的发病机制。我们使用临床遗传学和计算机辅助面部表型分析来描述 KIS 的表型谱。然后,我们使用基于序列的分析、3D 分子力学和动态蛋白质建模以及体外电生理和功能方法来研究编码 TASK3 通道的变异的功能影响。
我们描述了 KIS 患者的更广泛的遗传和表型变异性,在一个个体队列中确定了另一个突变热点 p.Arg131,并证明了这种神经发育障碍的共同特征,包括运动和言语延迟、智力障碍、早期喂养困难、肌肉张力减退、行为异常和发育不良。计算蛋白质建模和体外电生理研究发现 KCNK9 变体对 TASK3 通道功能的影响具有变异性,确定了导致电导增加和减少的变体。然而,KCNK9 遗传变异对通道功能最一致的功能影响是改变通道调节。
本研究扩展了我们对 KIS 机制的理解,证明了其复杂的病因学,包括通道功能的增益和损失以及通道调节的一致损失。这些数据可迅速应用于诊断策略,因为 KIS 不能仅从临床特征来识别,因此应进行分子诊断。此外,我们的数据表明,可能需要独特的治疗策略来解决 KCNK9 变异对通道功能和调节的特定功能后果。